Adult Allergy Action Plan
- 10 September 2024
- Healthcare News
The latest editorial from Clinical & Experimental Allergy highlights the need for adult-specific Allergy Action Plans (AAPs), especially for those at risk of anaphylaxis. Historically, AAPs have focused on paediatric care, but adults face different challenges, such as self-recognition of symptoms and self-administration of adrenaline auto-injectors (AAIs) in various settings.
In 2017, a national audit revealed that 46% of adults prescribed adrenaline injectors were not provided with an emergency plan, leading the British Society for Allergy and Clinical Immunology (BSACI) to develop an adult AAP. This plan ensures clear, effective guidelines, including symptom recognition, adrenaline administration, and emergency protocols.
BSACI’s Adult AAP is a collaborative effort between BSACI, Allergy UK and Anaphylaxis UK, informed by feedback from global allergy organisations and national health guidelines. Unlike paediatric plans, this version is geared towards adults self-managing their condition. The plan highlights key symptoms such as breathing difficulties, providing detailed instructions on when to administer adrenaline and how to manage allergic reactions.
The AAP has been reviewed and updated in line with UK Medicines and Healthcare Products Regulatory Agency (MHRA) guidelines. It is freely accessible and aims to improve adult care in managing anaphylaxis, filling a gap in current allergy action protocols. This initiative marks a critical step in adult allergy care, ensuring better preparedness and outcomes for those at risk.
You can get paediatric and Adult Allergy Action Plans here: Allergy Management Plans | Anaphylaxis UK
